Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

SUMIT SAWHNEY

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1548263353
CMS profile
341792
Location
CORAL SPRINGS, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$18,768.89

239 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

By paying entity

PY2022 · entire year · sorted by reported total

Page 3 of 5; records 101–150 of 239 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

SUMIT SAWHNEY

NPI 1548263353 · CMS profile ID 341792

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

CORAL SPRINGS, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 5; records 101–150 of 239 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1548263353?year=2022&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
SUMIT SAWHNEY, NPI 1548263353, CMS profile ID 341792. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 5; records 101–150 of 239 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1548263353?year=2022&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). SUMIT SAWHNEY, NPI 1548263353, CMS profile ID 341792. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 5; records 101–150 of 239 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1548263353?year=2022&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
SUMIT SAWHNEY, NPI 1548263353, CMS profile ID 341792, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 5; records 101–150 of 239 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1548263353?year=2022&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

239 matching records · $18,768.89 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 239 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–150 of 239.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
ABBVIE INC. $18.2007/18/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891529943 CMS
Celgene Corporation $16.0107/14/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932519179 CMS
Incyte Corporation $20.0007/13/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 943017315 CMS
AstraZeneca Pharmaceuticals LP $21.5707/12/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 915779251 CMS
E.R. Squibb & Sons, L.L.C. $17.8607/11/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932519177 CMS
Seagen Inc. $11.8407/08/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 904099655 CMS
Rigel Pharmaceuticals, Inc. $30.1807/07/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 962273849 CMS
PFIZER INC. $14.4507/06/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 949194901 CMS
PFIZER INC. $0.5407/06/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 949197717 CMS
TOLMAR Pharmaceuticals, Inc. $3.1507/06/2022 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1061019797 CMS
TOLMAR Pharmaceuticals, Inc. $18.1607/06/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 954453629 CMS
EISAI INC. $24.8306/30/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 908090797 CMS
Janssen Biotech, Inc. $19.7006/29/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885789709 CMS
Pharmacosmos Therapeutics Inc. $24.4006/29/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 959146333 CMS
GENZYME CORPORATION $4,530.0006/28/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 938832111 CMS
GENZYME CORPORATION $137.9806/28/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 938832113 CMS
GENZYME CORPORATION $203.1706/28/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 938832115 CMS
GENZYME CORPORATION $139.1906/28/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 938832117 CMS
GENZYME CORPORATION $4.4806/28/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 938832119 CMS
GENZYME CORPORATION $16.6006/28/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 938832121 CMS
ARRAY BIOPHARMA INC $3.8406/27/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 949183013 CMS
PFIZER INC. $10.1006/27/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 949183011 CMS
Janssen Biotech, Inc. $19.7306/23/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885789769 CMS
AstraZeneca Pharmaceuticals LP $19.8906/22/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 915869039 CMS
E.R. Squibb & Sons, L.L.C. $0.8706/21/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932519161 CMS
E.R. Squibb & Sons, L.L.C. $23.0706/21/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932519163 CMS
EMD Serono, Inc. $20.0006/20/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 941529077 CMS
PFIZER INC. $18.6906/14/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 949163779 CMS
Seagen Inc. $21.5406/13/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 904099619 CMS
Genentech USA, Inc. $17.8306/09/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 950772809 CMS
BeiGene USA, Inc. $15.8106/08/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 940793487 CMS
Janssen Biotech, Inc. $16.9806/08/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885789757 CMS
Janssen Biotech, Inc. $19.2406/08/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885789763 CMS
Bayer HealthCare Pharmaceuticals Inc. $22.9806/07/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 929833047 CMS
EISAI INC. $24.8806/06/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 908090809 CMS
GENZYME CORPORATION $14.3806/03/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 938832087 CMS
JAZZ PHARMACEUTICALS INC. $22.8506/02/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 951357489 CMS
Janssen Biotech, Inc. $975.0006/01/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885789657 CMS
Janssen Biotech, Inc. $22.3205/31/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885789673 CMS
GENZYME CORPORATION $22.9505/26/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 938832075 CMS
GlaxoSmithKline, LLC. $430.0005/26/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944935187 CMS
ABBVIE INC. $20.7805/25/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891529941 CMS
Incyte Corporation $25.7005/24/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 943017287 CMS
Amgen Inc. $16.5605/23/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939937913 CMS
E.R. Squibb & Sons, L.L.C. $15.8305/18/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932519155 CMS
AstraZeneca Pharmaceuticals LP $19.7305/17/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 915868007 CMS
Lilly USA, LLC $16.0405/17/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918312819 CMS
AstraZeneca Pharmaceuticals LP $2,275.0005/16/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 914894787 CMS
Merck Sharp & Dohme LLC $19.9205/16/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944348185 CMS
Foundation Medicine, Inc. $14.3205/11/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 924046057 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $20,014.17 350
PY2020 $16,177.80 217
PY2021 $20,752.98 208
PY2022 $18,768.89 239
PY2023 $9,674.24 144
PY2024 $9,539.17 40
PY2025 $7,888.12 101

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $206,255.96 9
PY2024 Principal investigator $160,856.21 10
PY2023 Recipient $78,386.10 5
PY2023 Principal investigator $157,976.35 15
PY2022 Recipient $5,836.00 1
PY2022 Principal investigator $57,850.69 13
PY2021 Principal investigator $252,909.97 11
PY2020 Principal investigator $4,000.00 1

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

9 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $37,664.20 11/03/2025 Non-covered Recipient Entity
Advanced Research Llc
A PHASE 3, TWO-STAGE, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY COMPARING MEZIGDOMIDE (CC-92480), BORTEZOMIB AND DEXAMETHASONE (MEZIVd) VERSUS POMALIDOMIDE, BORTEZOMIB AND DEXAMETHASONE (PVd) IN SUBJECTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): SUCCESSOR-1 No dispute reported 06/30/2026 1235999279
Principal investigator 1 GENZYME CORPORATION $17,754.00 10/30/2025 Non-covered Recipient Entity
Advanced Research LLC
A 52-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group, group sequential, phase 3 study to evaluate the efficacy and safety of rilzabrutinib in patients aged 10 to 55 years with sickle-cell disease No dispute reported 06/30/2026 1226089070
Principal investigator 1 Amgen Inc. $3,797.50 09/23/2025 Non-covered Recipient Entity
CORAZON USA, LLC
A Postmarketing Prospective Cohort Study of Melanoma Patients Treated With IMLYGIC in Clinical Practice to Characterize Risk of Herpetic Infection Among Patients, Close Contacts, Health Care Providers & Long-term Safety in Treated Patients No dispute reported 06/30/2026 1246640523
Principal investigator 1 GENZYME CORPORATION $13,838.00 05/27/2025 Non-covered Recipient Entity
Advanced Research LLC
A Phase 3, multicenter, randomized, double-bline, placebo controlled, parallel-group study with an open-label period and long-term extension to assess the efficacy and safety of rilzabrutinib in participants with warm autoimmune hemolytic anemia (WAIHA) No dispute reported 06/30/2026 1226089031
Principal investigator 1 Eli Lilly and Company $765.54 05/08/2025 Non-covered Recipient Entity
ADVANCED RESEARCH LLC
A PHASE 3 OPEN-LABEL, RANDOMIZED STUDY OF PIRTOBRUTINIB (LOXO-305) VERSUS BENDAMUSTINE PLUS RITUXIMAB IN UNTREATED PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA No dispute reported 06/30/2026 1187876085
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $1,687.39 03/19/2025 Non-covered Recipient Entity
Advanced Research
A Phase 3, Open-label, Randomized Study to Compare the Efficacy and Safety of Luspatercept vs Epoetin Alfa for the Treatment of Anemia Due to Revised International Prognostic Scoring System Very Low, Low, or Intermediate Risk Myelodysplastic Syndrome in Erythropoiesis-Stimulating Agent naive Participants who are Non-Transfusion Dependent No dispute reported 06/30/2026 1235999319
Principal investigator 1 Eli Lilly and Company $12,778.75 02/24/2025 Non-covered Recipient Entity
ADVANCED RESEARCH LLC
A PHASE 3 OPEN-LABEL, RANDOMIZED STUDY OF PIRTOBRUTINIB (LOXO-305) VERSUS BENDAMUSTINE PLUS RITUXIMAB IN UNTREATED PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA No dispute reported 06/30/2026 1187875883
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $7,016.39 01/27/2025 Non-covered Recipient Entity
Advanced Research
A PHASE 3, TWO-STAGE, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY COMPARING MEZIGDOMIDE (CC-92480), BORTEZOMIB AND DEXAMETHASONE (MEZIVd) VERSUS POMALIDOMIDE, BORTEZOMIB AND DEXAMETHASONE (PVd) IN SUBJECTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): SUCCESSOR-1 No dispute reported 06/30/2026 1235999317
Principal investigator 1 Celgene Corporation $110,954.19 01/10/2025 Non-covered Recipient Entity
Advanced Research Llc
A PHASE 3, TWO-STAGE, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY COMPARING MEZIGDOMIDE (CC-92480), BORTEZOMIB AND DEXAMETHASONE (MEZIVd) VERSUS POMALIDOMIDE, BORTEZOMIB AND DEXAMETHASONE (PVd) IN SUBJECTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): SUCCESSOR-1 No dispute reported 06/30/2026 1222306425